Nancy J. Hutson - 12 Jun 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Director
Issuer ticker: BCRX
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 16:20:08 UTC
Prior SEC filing: 16 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Nancy J. Hutson filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 16 Jun 2025.

Key facts

This page summarizes Nancy J. Hutson's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2025, 16:20.

Change

Previous filing in this sequence was filed on 16 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001379222 Primary reporting owner

Hutson Nancy J

Relationship: Director
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 16 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value: $0
Shares: +12,500
Change %: +14%
Price: $0.000000
Shares after: 99,138
Date: 12 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Automatic Stock Option Grant

Award

Transaction value: $0
Shares: +27,181
Change %
Price: $0.000000
Shares after: 27,181
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,181
Exercise price: $10.40
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Footnote F2

Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

SEC remarks

Exhibit List - Exhibit 24 - Power of Attorney